Amylyx Pharmaceuticals, Inc. - Common Stock (AMLX)
3.6500
+0.1400 (3.99%)
Amylyx Pharmaceuticals is a biotechnology company focused on the development of innovative therapeutics for neurodegenerative diseases
The company aims to address significant unmet medical needs, particularly in conditions such as amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease, through its proprietary drug candidates that target underlying biological processes. By leveraging scientific expertise and advanced research techniques, Amylyx is committed to delivering effective treatment options that enhance the quality of life for patients affected by these challenging conditions.
Crude Oil Rises Sharply; US Homebuilder Sentiment Surges In Novembermarkets/com
Via Benzinga · November 18, 2024
Twist Bioscience Posts Upbeat Results, Joins Tesla, Amylyx Pharmaceuticals, Regenxbio And Other Big Stocks Moving Higher On Mondaybenzinga.com
Via Benzinga · November 18, 2024
This Robinhood Analyst Turns Bullish; Here Are Top 5 Upgrades For Mondaybenzinga.com
Via Benzinga · November 18, 2024
Why Amylyx Pharmaceuticals Stock Was So Healthy This Weekfool.com
The company seems to have a winner on its hands with a drug that targets a rare genetic disorder.
Via The Motley Fool · October 18, 2024
Reneo Pharmaceuticals And 2 Other Stocks Under $5 Executives Are Buyingbenzinga.com
Via Benzinga · September 17, 2024
NVIDIA To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Fridaybenzinga.com
Via Benzinga · July 12, 2024
Why Is Small Cap Amylyx Pharmaceuticals Stock Trading Higher On Wednesday?benzinga.com
Amylyx Pharmaceuticals acquired avexitide from Eiger BioPharmaceuticals Inc. for $35.1 million. Avexitide, a GLP-1 receptor antagonist, ready for Phase 3 trial for post-bariatric hypoglycemia and congenital hyperinsulinism.
Via Benzinga · July 10, 2024
AMLX Stock Earnings: Amylyx Pharma Misses EPS, Misses Revenue for Q1 2024investorplace.com
AMLX stock results show that Amylyx Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via InvestorPlace · May 9, 2024
Amylyx Pharmaceuticals' Investigational Drug Shows Improved Pancreatic Function In Patients With Inherited Disorderbenzinga.com
Amylyx's AMX0035 data in treating Wolfram syndrome, with interim data indicating positive effects on diabetes progression, visual decline, and overall disease burden. Safety profile consistent.
Via Benzinga · April 10, 2024
Amylyx Stock Crashes 80% After Approved ALS Drug Fails Its Pivotal Testinvestors.com
The company could now pull Relyvrio off the market.
Via Investor's Business Daily · March 8, 2024
CNS Disorder-Focused Seelos Therapeutics Plunges To 52-Week Low - Here's Whybenzinga.com
Seelos Therapeutics updates Phase 2/3 HEALEY ALS trial with SLS-005, showing potential efficacy in subgroup analysis. Explore the latest data on ALS treatment with SLS-005."
Via Benzinga · March 19, 2024
3 Pharma Stocks to Sell in March Before They Crash & Burninvestorplace.com
Discover top pharma stocks to sell in March before they plummet. Learn why ACAD, AMLX and WST are on the list for urgent sell-off decisions.
Via InvestorPlace · March 14, 2024
Dow Gains Over 100 Points; AerSale Shares Plunge After Q4 Resultsbenzinga.com
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite dipping around 0.5% on Friday. The Dow traded up 0.27% to 38,894.21 while the NASDAQ fell 0.51% to 16,190.52. The S&P 500 also fell, dropping, 0.20% to 5,146.8.
Via Benzinga · March 8, 2024
Stocks Fall As Chipmakers Retreat From Highs, Bitcoin Pulls Back After $70,000, Gold Rises To $2,200: What's Driving Markets Friday?benzinga.com
The stock market is navigating a mixed closing session this week, with the S&P 500 and Nasdaq 100 struggling to stave off a weekly downturn.
Via Benzinga · March 8, 2024
Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Sessionbenzinga.com
Shares of Marvell Technology, Inc. (NASDAQMRVL) fell sharply during Friday’s session after the company reported fourth-quarter financial results and issued weak Q1 guidance.
Via Benzinga · March 8, 2024
Crude Oil Falls Over 1%; Willdan Group Shares Spike Higherbenzinga.com
U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 80 points on Friday. The Dow traded up 0.21% to 38,874.05 while the NASDAQ fell 0.42% to 16,204.26. The S&P 500 also fell, dropping, 0.13% to 5,150.72.
Via Benzinga · March 8, 2024
Why Is Neurodegenerative Diseases-Focused Amylyx Pharmaceuticals Stock Plunging On Friday?benzinga.com
Amylyx Pharmaceuticals' AMX0035 trial results for ALS. Amylyx plans regulatory discussions and potential market actions. AMX0035's ongoing studies in PSP and Wolfram syndrome.
Via Benzinga · March 8, 2024
Nasdaq Gains Over 50 Points; US Economy Adds 275,000 Jobs In Februarybenzinga.com
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining over 50 points on Friday. Following the market opening Friday, the Dow traded up 0.04% to 38,805.52 while the NASDAQ rose 0.41% to 16,339.39. The S&P 500 also rose, gaining, 0.23% to 5,169.38.
Via Benzinga · March 8, 2024